Showing papers on "Batroxobin published in 2015"
TL;DR: A self-assembling nanofibrous peptide hydrogel that on its own can act as a physical barrier to blood loss and demonstrates a facile method for surgical hemostasis even in the presence of anticoagulant therapies.
Abstract: Controlling perioperative bleeding is of critical importance to minimize hemorrhaging and fatality. Patients on anticoagulant therapy such as heparin have diminished clotting potential and are at risk for hemorrhaging. Here we describe a self-assembling nanofibrous peptide hydrogel (termed SLac) that on its own can act as a physical barrier to blood loss. SLac was loaded with snake-venom derived Batroxobin (50 μg/mL) yielding a drug-loaded hydrogel (SB50). SB50 was potentiated to enhance clotting even in the presence of heparin. In vitro evaluation of fibrin and whole blood clotting helped identify appropriate concentrations for hemostasis in vivo. Batroxobin-loaded hydrogels rapidly (within 20s) stop bleeding in both normal and heparin-treated rats in a lateral liver incision model. Compared to standard of care, Gelfoam, and investigational hemostats such as Puramatrix, only SB50 showed rapid liver incision hemostasis post surgical application. This snake venom-loaded peptide hydrogel can be applied via syringe and conforms to the wound site resulting in hemostasis. This demonstrates a facile method for surgical hemostasis even in the presence of anticoagulant therapies.
56 citations
TL;DR: Prophylactic use of Batroxobin provided an effective and cheap method for reducing blood loss without coagulopathy during or after operations and effectively reduced the total amount of perioperative blood loss.
Abstract: Objective
Our objective was to evaluate the efficacy and safety of Batroxobin on blood loss during spinal operations.
14 citations
TL;DR: Batroxobin has multiple beneficial effects on SCI, indicating a potential clinical application, and is hypothesized to exhibit protective effects following SCI by promoting the expression of VEGF to reduce the levels of apoptosis in a rat model of SCI.
Abstract: The host response to spinal cord injury (SCI) can lead to an ischemic environment that can induce cell death. Therapeutic interventions using neurotrophic factors have focused on the prevention of such reactions in order to reduce this cell death. Vascular endothelial growth factor (VEGF) is a potent angiogenic and vascular permeability factor. We hypothesized in this study that batroxobin would exhibit protective effects following SCI by promoting the expression of VEGF to reduce the levels of apoptosis in a rat model of SCI. Ninety adult female Sprague Dawley rats were divided randomly into sham injury (group I), SCI (group II) and batroxobin treatment (group III) groups. The Basso-Bettie-Bresnahan (BBB) scores, number of apoptotic cells and expression of VEGF were assessed at 1, 3, 5, 7, 14 and 28 days post-injury. The BBB scores were significantly improved in group III compared with those in group II between days 5 and 28 post-injury (P<0.05). At each time-point subsequent to the injury, the number of apoptotic cells in group III was reduced compared with that in group II. Compared with group II, treatment with batroxobin significantly increased the expression of VEGF from day 3 until 2 weeks post-SCI (P<0.05), while no significant difference was observed at day 28. These data suggest that batroxobin has multiple beneficial effects on SCI, indicating a potential clinical application.
6 citations
TL;DR: In this article, the authors evaluated the in vivo efficacy of 915 MHz percutaneous coagulation in the treatment of hepatic artery injury and found that the hemostatic effects of this method were better than drug injection, and the amount of bleeding was significantly lower.
2 citations
25 Jul 2015
TL;DR: It is confirmed that batroxobin injection can significantly reduce the infarct area, promote the recovery of neurological functions, and delay the development of PIS to improve the prognosis of patients with PIS.
Abstract: Keywords: Batroxobin; Progressive ischemic stroke (PIS); MMP-2; MMP-9 Abstract. Effects of batroxobin on progressive ischemic stroke (PIS) and serum MMP-2 and MMP-9 expressions in patients with PIS were investigated. 160 Hospitalized patients with acute progressive ischemic stroke were randomly divided into a treatment group (n=80) and a control group (n=80). Patients in the treatment group were treated with the conventional therapy combined with batroxobin injection, in which 10u, 5u and 5u of batroxobin injection were successively administered once every other day, respectively, and patients in the control group were treated with the conventional therapy alone. Therapeutic effects on PIS and patients' NIHSS scores between the two groups were compared. Serum MMP-2 and MMP-9 expressions before and after the treatment were detected with enzyme-linked immunosorbent assay (ELASE). The results showed that the total effective rate of patients in the treatment group was 91.25%, significantly better than that in the control group, which was 78.75% (P <0.05); NIHSS scores after the treatment were significantly lover than those before the treatment in both groups; compared with those before the treatment, MMP-2 and MMP-9 levels were significantly decreased after the treatment (P<0.05); differences in NIHSS scores and serum MMP-2 and MMP-9 levels between the two groups were significant after the treatment (P<0.05). Batroxobin injection can be used for the treatment of PIS, with a definite therapeutic effect. It is confirmed that batroxobin injection can significantly reduce the infarct area, promote the recovery of neurological functions, and delay the development of PIS to improve the prognosis of patients with PIS, which may be closely related to its reducing the level of MMP-2 and MMP-9 in the body.
1 citations